Uniqure N.V. (QURE)

$24.93 -2.12 (-7.84%)
Market Cap 1.71B
Revenue (ttm) 16.10M
Net Income (ttm) -198.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,235.84%
Debt to Equity Ratio 0.33
Volume 1,814,900
Avg Vol 2,284,014
Day's Range N/A - N/A
Shares Out 63.07M
Stochastic %K 47%
Beta 0.87
Analysts Strong Sell
Price Target $39.27

Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial t...

Industry: Biotechnology
Sector: Healthcare
Phone: 31 20 240 6000
Address:
Paasheuvelweg 25, Amsterdam, Netherlands
OfficialStocktwitsUser
OfficialStocktwitsUser May. 19 at 12:46 AM
$QURE RSI: 67.48, MACD: 2.6740 Vol: 4.51, MA20: 22.23, MA50: 18.77 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SafeMargins
SafeMargins May. 18 at 3:38 PM
$QURE https://www.theguardian.com/us-news/2026/may/16/fda-tracy-beth-hoeg-drug-chief-departs
1 · Reply
maphere
maphere May. 15 at 8:30 PM
$RGNX Looking at $QURE 3 month timeline makes me feel a little bit better about future share price for Regenxbio.
1 · Reply
Thinkingman91
Thinkingman91 May. 14 at 7:05 PM
$QURE are charts magical
0 · Reply
Ontherag
Ontherag May. 14 at 6:19 PM
$QURE Betting on FDA to reverse decision is a horrible investment decision
0 · Reply
Dkll303
Dkll303 May. 14 at 10:41 AM
$QURE can’t get there with the CEO selling shares since 2020 !!!! But then he is an ex cold calling stockbroker, you expected the truth from him ??? As you bought the offering at $47 !!!!
0 · Reply
Dkll303
Dkll303 May. 14 at 10:40 AM
$QURE more lies
0 · Reply
Jcljack26
Jcljack26 May. 13 at 7:50 PM
$QURE This should be $35+ while we wait for FDA to get their heads out of their asses
0 · Reply
GIG888888888
GIG888888888 May. 13 at 12:52 PM
$QURE exiting my short pos here, if this thing touches $26 I’ll be back, but if it touches 33 today it’s gone.
0 · Reply
stu4
stu4 May. 13 at 9:53 AM
$QURE big money bought the offering , lol , at $47 and then Matt K slipped them a Mikey ….and sold 9M dollars worth of stock, knowing his placebo didn’t exist !! lol Who were those BIG MONEY CLOWNS that Matt fcuked over ??? And Matt’s , HITS , just keep on coming , haha
0 · Reply
Latest News on QURE
uniQure price target lowered to $50 from $70 at H.C. Wainwright

2026-05-07T03:31:34.000Z - 12 days ago

uniQure price target lowered to $50 from $70 at H.C. Wainwright

uniQure price target raised to $28 from $14 at Stifel

2026-05-05T15:40:54.000Z - 13 days ago

uniQure price target raised to $28 from $14 at Stifel

uniQure Earnings Call Transcript: Q1 2026

May 5, 2026, 8:30 AM EDT - 13 days ago

uniQure Earnings Call Transcript: Q1 2026

uniQure reports Q1 EPS (85c), consensus (75c)

2026-05-05T11:53:55.000Z - 13 days ago

uniQure reports Q1 EPS (85c), consensus (75c)

uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates

May 5, 2026, 7:05 AM EDT - 13 days ago

uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates

uniQure price target raised to $37 from $31 at Chardan

2026-04-30T22:15:49.000Z - 18 days ago

uniQure price target raised to $37 from $31 at Chardan

uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease

Apr 30, 2026, 7:05 AM EDT - 18 days ago

uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease

uniQure to Announce First Quarter 2026 Financial Results

Apr 28, 2026, 7:05 AM EDT - 20 days ago

uniQure to Announce First Quarter 2026 Financial Results

uniQure price target raised to $10 from $9 at Goldman Sachs

2026-04-20T10:22:30.000Z - 4 weeks ago

uniQure price target raised to $10 from $9 at Goldman Sachs

uniQure call volume above normal and directionally bullish

2026-04-17T18:45:16.000Z - 4 weeks ago

uniQure call volume above normal and directionally bullish

uniQure put volume heavy and directionally bearish

2026-04-10T16:35:19.000Z - 5 weeks ago

uniQure put volume heavy and directionally bearish

uniQure put volume heavy and directionally bearish

2026-04-08T15:15:14.000Z - 5 weeks ago

uniQure put volume heavy and directionally bearish

uniQure Investors Sue Company Over Huntington’s Disease Drug Study Claims

2026-03-24T16:34:35.000Z - 7 weeks ago

uniQure Investors Sue Company Over Huntington’s Disease Drug Study Claims

uniQure price target lowered to $25 from $31 at Barclays

2026-03-23T09:35:09.000Z - 2 months ago

uniQure price target lowered to $25 from $31 at Barclays

uniQure upgraded to Outperform from Neutral at Mizuho

2026-03-10T20:27:50.000Z - 2 months ago

uniQure upgraded to Outperform from Neutral at Mizuho

uniQure upgraded at Mizuho on potential improvement in regulatory outlook

2026-03-10T20:26:57.000Z - 2 months ago

uniQure upgraded at Mizuho on potential improvement in regulatory outlook

uniQure shares positioned for ‘value inflection,’ says H.C. Wainwright

2026-03-10T10:20:33.000Z - 2 months ago

uniQure shares positioned for ‘value inflection,’ says H.C. Wainwright

This biotech's stock is soaring after a ‘polarizing' FDA official is stepping down

Mar 9, 2026, 9:18 AM EDT - 2 months ago

This biotech's stock is soaring after a ‘polarizing' FDA official is stepping down

Federal health officials attacked an Amsterdam-based biotech company seeking approval of a Huntington's disease treatment and accused it of lying

Mar 5, 2026, 6:01 PM EST - 2 months ago

Federal health officials attacked an Amsterdam-based biotech company seeking approval of a Huntington's disease treatment and accused it of lying

FDA official calls UniQure's gene therapy a 'failed' treatment for Huntington's disease

Mar 5, 2026, 2:42 PM EST - 2 months ago

FDA official calls UniQure's gene therapy a 'failed' treatment for Huntington's disease

Sr. FDA official calls Uniqure's Huntington's disease treatment a failure

Mar 5, 2026, 1:11 PM EST - 2 months ago

Sr. FDA official calls Uniqure's Huntington's disease treatment a failure

FDA official says UniQure fell short on Huntington's trial, defends new study request

Mar 4, 2026, 11:01 PM EST - 2 months ago

FDA official says UniQure fell short on Huntington's trial, defends new study request

uniQure Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 10:30 AM EST - 2 months ago

uniQure Transcript: TD Cowen 46th Annual Health Care Conference

uniQure Earnings Call Transcript: Q4 2025

Mar 2, 2026, 8:00 AM EST - 2 months ago

uniQure Earnings Call Transcript: Q4 2025

FDA tells UniQure study data insufficient for brain disorder therapy application

Mar 2, 2026, 7:22 AM EST - 2 months ago

FDA tells UniQure study data insufficient for brain disorder therapy application

uniQure Announces 2025 Financial Results and Provides Recent Company Updates

Mar 2, 2026, 7:05 AM EST - 2 months ago

uniQure Announces 2025 Financial Results and Provides Recent Company Updates

QURE INVESTOR REMINDER: uniQure N.V. Investors Have Until April 13, 2026 To Seek Lead Plaintiff Role

Feb 25, 2026, 6:00 PM EST - 2 months ago

QURE INVESTOR REMINDER: uniQure N.V. Investors Have Until April 13, 2026 To Seek Lead Plaintiff Role

uniQure to Announce 2025 Financial Results

Feb 23, 2026, 7:05 AM EST - 3 months ago

uniQure to Announce 2025 Financial Results

UniQure N.V. (QURE) Securities Fraud: Contact Berger Montague To Discuss Your Rights

Feb 18, 2026, 10:06 AM EST - 3 months ago

UniQure N.V. (QURE) Securities Fraud: Contact Berger Montague To Discuss Your Rights

UNIQURE N.V. (QURE) INVESTOR ALERT Investors With Large Losses in uniQure N.V.

Feb 17, 2026, 8:16 AM EST - 3 months ago

UNIQURE N.V. (QURE) INVESTOR ALERT Investors With Large Losses in uniQure N.V.

uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease

Feb 6, 2026, 7:05 AM EST - 3 months ago

uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease

uniQure Announces Type A Meeting Scheduled with FDA

Jan 9, 2026, 7:05 AM EST - 4 months ago

uniQure Announces Type A Meeting Scheduled with FDA

Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years

Dec 7, 2025, 12:01 PM EST - 5 months ago

Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years

uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease

Dec 4, 2025, 7:05 AM EST - 5 months ago

uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease

uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - QURE

Nov 14, 2025, 4:17 AM EST - 6 months ago

uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - QURE

uniQure Earnings Call Transcript: Q3 2025

Nov 10, 2025, 8:30 AM EST - 6 months ago

uniQure Earnings Call Transcript: Q3 2025

uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 10, 2025, 7:05 AM EST - 6 months ago

uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update

uniQure to Announce Third Quarter 2025 Financial Results

Nov 6, 2025, 7:05 AM EST - 6 months ago

uniQure to Announce Third Quarter 2025 Financial Results

OfficialStocktwitsUser
OfficialStocktwitsUser May. 19 at 12:46 AM
$QURE RSI: 67.48, MACD: 2.6740 Vol: 4.51, MA20: 22.23, MA50: 18.77 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SafeMargins
SafeMargins May. 18 at 3:38 PM
$QURE https://www.theguardian.com/us-news/2026/may/16/fda-tracy-beth-hoeg-drug-chief-departs
1 · Reply
maphere
maphere May. 15 at 8:30 PM
$RGNX Looking at $QURE 3 month timeline makes me feel a little bit better about future share price for Regenxbio.
1 · Reply
Thinkingman91
Thinkingman91 May. 14 at 7:05 PM
$QURE are charts magical
0 · Reply
Ontherag
Ontherag May. 14 at 6:19 PM
$QURE Betting on FDA to reverse decision is a horrible investment decision
0 · Reply
Dkll303
Dkll303 May. 14 at 10:41 AM
$QURE can’t get there with the CEO selling shares since 2020 !!!! But then he is an ex cold calling stockbroker, you expected the truth from him ??? As you bought the offering at $47 !!!!
0 · Reply
Dkll303
Dkll303 May. 14 at 10:40 AM
$QURE more lies
0 · Reply
Jcljack26
Jcljack26 May. 13 at 7:50 PM
$QURE This should be $35+ while we wait for FDA to get their heads out of their asses
0 · Reply
GIG888888888
GIG888888888 May. 13 at 12:52 PM
$QURE exiting my short pos here, if this thing touches $26 I’ll be back, but if it touches 33 today it’s gone.
0 · Reply
stu4
stu4 May. 13 at 9:53 AM
$QURE big money bought the offering , lol , at $47 and then Matt K slipped them a Mikey ….and sold 9M dollars worth of stock, knowing his placebo didn’t exist !! lol Who were those BIG MONEY CLOWNS that Matt fcuked over ??? And Matt’s , HITS , just keep on coming , haha
0 · Reply
Kenwonc
Kenwonc May. 13 at 6:30 AM
$QURE few more direct news and the shorts should be running.
0 · Reply
History101
History101 May. 13 at 1:40 AM
$REPL $QURE good article, more pressure to let patients with rare diseases, or hopeless terminal diseases, try whatever they want to combat their illnesses... https://www.theblaze.com/columns/opinion/the-fda-seems-to-care-more-about-celebrities-than-sick-americans
1 · Reply
Ontherag
Ontherag May. 13 at 1:33 AM
$QURE Gonna get approved tomorrow because the FDA corrupt right?
0 · Reply
Ontherag
Ontherag May. 13 at 1:29 AM
$QURE masssssive
0 · Reply
mikesterz7
mikesterz7 May. 12 at 9:47 PM
$REPL $QURE Marty Makary has resigned as commissioner of the Food and Drug Administration after weeks of mounting pressure from the Trump administration. 🔥🔥🔥
0 · Reply
GIG888888888
GIG888888888 May. 12 at 8:39 PM
$QURE yeah this was a nice bull trap, down she goes tomorrow buy the rumor sell the news.
0 · Reply
Ginelle2424
Ginelle2424 May. 12 at 8:23 PM
$QURE 💯💯
0 · Reply
StocktwitsNews
StocktwitsNews May. 12 at 7:31 PM
REPL, QURE Stocks Rise Amid Makary’s Reported Resignation As FDA Chief $REPL $QURE $PPH $IHE https://stocktwits.com/news/equity/markets/repl-qure-stocks-rise-amid-makary-reported-resignation-as-fda-chief/cZXXVRmReiy
0 · Reply
LotOfAction
LotOfAction May. 12 at 7:18 PM
$QURE Added little more
0 · Reply
trendmaker
trendmaker May. 12 at 5:58 PM
$QURE thinking of adding here !
0 · Reply
Reapthewhirlwind69
Reapthewhirlwind69 May. 12 at 5:50 PM
$QURE Increased position here
0 · Reply
Ginelle2424
Ginelle2424 May. 12 at 5:25 PM
$QURE Goodbye Marty - we will not miss you
0 · Reply